Formulation And Characterization of Lovastatin Tablets Enteric and Non-enteric Coated with Polymer Blends for Colon-specific Drug Release
DOI:
https://doi.org/10.52783/jns.v14.2412Keywords:
Colon-specific drug delivery, Lovastatin, Inclusion complex, Compression-coated tablets, β-cyclodextrin, Polymer swelling behaviourAbstract
The study focused on developing a colon-specific drug delivery system for Lovastatin using β-cyclodextrin inclusion complexes and compression-coated tablets. The inclusion complexes were prepared via a kneading method, where Lovastatin was mixed with β-cyclodextrin in a 1:2 molar ratio. Core tablets were formulated using direct compression, incorporating Lovastatin, β-cyclodextrin, and excipients. These cores were subsequently coated with polymer blends of Inulin with either HPMC or Ethyl Cellulose to achieve colon-specific drug release. The swelling behaviour of the polymers was evaluated in an acidic medium, revealing that HPMC exhibited significant swelling, while Ethyl Cellulose formed a film-like layer. The phase solubility study indicated a 1:2 complex formation between Lovastatin and β-cyclodextrin, enhancing drug solubility. XRD and DSC analyses suggested a transition of Lovastatin to an amorphous state within the complex. Drug release studies demonstrated that selected formulations effectively protected the drug in the upper gastrointestinal tract and ensured release in the colon. This research highlights the potential of the developed system for targeted delivery of Lovastatin to the colon, which could improve therapeutic outcomes for conditions like hypercholesterolemia.
Downloads
Metrics
References
ASHFORD, M. & FELL, J. T. 1994. Targeting drugs to the colon: delivery systems for oral administration. J Drug Target, 2, 241-57.
BAI, J. P., CHANG, L. L. & GUO, J. H. 1995. Targeting of peptide and protein drugs to specific sites in the oral route. Crit Rev Ther Drug Carrier Syst, 12, 339-71.
FUKUI, E., MIYAMURA, N. & KOBAYASHI, M. 2001. An in vitro investigation of the suitability of press-coated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydrophobic additives in the outer shell for colon targeting. Journal of Controlled Release, 70, 97-107.
IBEKWE, V. C., KHELA, M. K., EVANS, D. F. & BASIT, A. W. 2008. A new concept in colonic drug targeting: a combined pH‐responsive and bacterially‐triggered drug delivery technology. Alimentary pharmacology & therapeutics, 28, 911-916.
LIU, F., LIZIO, R., MEIER, C., PETEREIT, H.-U., BLAKEY, P. & BASIT, A. W. 2009. A novel concept in enteric coating: a double-coating system providing rapid drug release in the proximal small intestine. Journal of Controlled Release, 133, 119-124.
PEARNCHOB, N. & BODMEIER, R. 2003. Dry polymer powder coating and comparison with conventional liquid-based coatings for Eudragit® RS, ethylcellulose and shellac. European journal of pharmaceutics and biopharmaceutics, 56, 363-369.
SINGH, B. N. 2007. Modified-release solid formulations for colonic delivery. Recent patents on drug delivery & formulation, 1, 53-63.
SINHA, V. R., MITTAL, B. R., BHUTANI, K. K. & KUMRIA, R. 2004. Colonic drug delivery of 5-fluorouracil: an in vitro evaluation. International Journal of Pharmaceutics, 269, 101-108.
VAN DEN MOOTER, G. 2006. Colon drug delivery. Expert opinion on drug delivery, 3, 111-125.
WATTS, P. J. & LLLUM, L. 1997. Colonic drug delivery. Drug development and industrial pharmacy, 23, 893-913.
YANG, L., CHU, J. S. & FIX, J. A. 2002. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. International journal of pharmaceutics, 235, 1-15.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.